EcoDrugPlus

60s Ribosomal Protein L10

Ensembl ID : ENSACLG00000000472
Gene Symbol: LOC113013561
3 Cross references
407 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSACLG00000008012
Gene Symbol: LOC113028400
4 Cross references
341 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSACLG00000001074
Gene Symbol: LOC113020383
3 Cross references
324 Possible Orthologues:

60s Ribosomal Protein L26

Ensembl ID : ENSACLG00000001623
Gene Symbol: LOC113034576
3 Cross references
477 Possible Orthologues:

60s Ribosomal Protein L3

Ensembl ID : ENSACLG00000022545
Gene Symbol: LOC113020280
3 Cross references
338 Possible Orthologues:

60s Ribosomal Protein L30

Ensembl ID : ENSACLG00000014910
Gene Symbol: LOC113015129
3 Cross references
317 Possible Orthologues:

60s Ribosomal Protein L30

Ensembl ID : ENSACLG00000007160
Gene Symbol: LOC113015129
3 Cross references
317 Possible Orthologues:

60s Ribosomal Protein L35

Ensembl ID : ENSACLG00000018408
Gene Symbol: LOC113032919
4 Cross references
270 Possible Orthologues:

60s Ribosomal Protein L35

Ensembl ID : ENSACLG00000018708
Gene Symbol: LOC113034251
4 Cross references
270 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSACLG00000013533
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSACLG00000014403
Gene Symbol: ADAM17
3 Cross references
210 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSACLG00000027795
Gene Symbol: ADAMTS5
4 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).